TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10807815
Drug: Salbutamol MDI
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol MDI and 0.5 mL of saline solution (group II, n = 23)
Study: 8117556
Drug: Topical treatment
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatment with mucopolysaccharide polysulphate/salicylic acid cream
Study: 30607719
Drug: Photobiomodulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation therapy (PBMT) 300 J per thigh
Study: 28694341
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment with functional bracing
Study: 19808491
Drug: Radiofrequency catheter
Normalized name: CATHETER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiofrequency catheter ablation (RFA) with/without antiarrhythmic drug (AAD)
Study: 19808491
Drug: Antiarrhythmic drug
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic drug (AAD) alone
Study: 9891194
Drug: Chloral hydrate
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloral hydrate (CH) alone (70 mg/kg)
Study: 9891194
Drug: Chloral hydrate/hydroxyzine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloral hydrate/hydroxyzine (CH/H) (70 mg/kg CH + 2 mg/kg hydroxyzine)
Study: 8015507
Drug: 2 mg/24
Normalized name: testosterone 2 mg/24 hr transdermal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/24 h administration of oestradiol valerate
Study: 8015507
Drug: 1.5 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/day of percutaneous 17 beta-oestradiol
Study: 8015507
Drug: 0.05 mg/day
Normalized name: Lyllana 0.05 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg/day of transdermic oestradiol
Study: 2660632
Drug: Clemastine syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clemastine syrup
Study: 354474
Drug: 265 mg
Normalized name: doconexent 265 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 265 mg theophylline (150 mg slow-release)
Study: 354474
Drug: 265 mg
Normalized name: doconexent 265 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 265 mg theophylline + 7.5 mg hydroxyzine hydrochloride
Study: 31830776
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy plus probiotics (group B)
Study: 31830776
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy plus sulforaphane (group C)
Study: 31830776
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy only (group A)
Study: 28443690
Drug: 7 days
Normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 days of vaginal micronised progesterone tablets (Group A)
Study: 25818061
Drug: Bupropion, sustained-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion, sustained-release 150 mg, twice daily
Study: 23963057
Drug: Atomoxetine (ATX)
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atomoxetine (ATX) 0.5-1.8 mg/kg per day
Study: 23963057
Drug: Other early
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other early standard therapy (OEST, mainly methylphenidate)
Study: 20946437
Drug: Caffeine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (200 mg bi-hourly for 3 nights)
Study: 20946437
Drug: Placebo (indistinguishable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (indistinguishable gum bi-hourly for 3 nights)
Study: 17920770
Drug: First-line treatments
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line treatments including certain antidepressants (tricyclic antidepressants and dual reuptake inhibitors of both serotonin and norepinephrine)
Study: 17920770
Drug: Opioid analgesics
Normalized name: OPIOID ANALGESICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid analgesics and tramadol
Study: 17920770
Drug: Certain antiepileptic
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Certain antiepileptic and antidepressant medications, mexiletine, N-methyl-D-aspartate receptor antagonists, and topical capsaicin
Study: 9661537
Drug: Nurse-administered subcutaneous
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse-administered subcutaneous morphine
Study: 9661537
Drug: i.v. patient-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. patient-controlled analgesia morphine
Study: 1146857
Drug: Directive play
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Directive play therapy
Study: 1146857
Drug: Nondirective play
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nondirective play therapy
Study: 28342891
Drug: Group Acceptance
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Acceptance and Commitment Therapy (GACT)
Study: 22018333
Drug: Recommended Pharmacological
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommended Pharmacological Treatment (RPT)
Study: 17203122
Drug: atracurium (priming
Approvals — FDA: no, EMA: no, PMDA: no
Description: atracurium (priming with 0.05 mg/kg followed by 0.55 mg/kg after induction of anaesthesia)
Study: 14679270
Drug: Efalizumab, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efalizumab, 1 mg/kg, 12 weekly doses
Study: 9722127
Drug: oral ornidazole
Normalized name: ornidazole
DrugBank: Ornidazole (DB13026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral ornidazole 2 x 500 mg/day for 5 days
Study: 9722127
Drug: vaginal ornidazole
Normalized name: ornidazole
DrugBank: Ornidazole (DB13026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: vaginal ornidazole 500 mg/day for 5 days
Study: 9722127
Drug: oral secnidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral secnidazole 2 g in a single dose and vaginal ornidazole 500 mg/day for 5 days
Study: 9722127
Drug: oral secnidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral secnidazole 2 g in a single dose and vaginal metronidazole 2 x 500 mg/day for 7 days
Study: 9722127
Drug: oral ornidazole
Normalized name: ornidazole
DrugBank: Ornidazole (DB13026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral ornidazole 2 x 500 mg/day for 5 days and vaginal metronidazole 2 x 500 mg/day for 7 days
Study: 9722127
Drug: vaginal metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: vaginal metronidazole 2 x 500 mg/day for 7 days
Study: 7978130
Drug: Sufentanil 2
Normalized name: SUFentanil 250 MCG in 5 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 2 micrograms.ml‐1 in 0.9% sodium chloride
Study: 7978130
Drug: Sufentanil 2
Normalized name: SUFentanil 250 MCG in 5 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 2 micrograms.ml‐1 + adrenaline 2.5 micrograms.ml‐1
Study: 7978130
Drug: Sufentanil 2
Normalized name: SUFentanil 250 MCG in 5 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 2 micrograms.ml‐1 + clonidine 3 micrograms.ml‐1
Study: 2531992
Drug: IA (Intraarterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: IA (Intraarterial FUdR, 0.2 mg/kg/d x 14 days/month)
Study: 2531992
Drug: IA/IV (Intraarterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: IA/IV (Intraarterial FUdR + systemic 5‐FU 700 mg/m2/d x 3 days/month)
Study: 31834936
Drug: Smartphone application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smartphone application providing information and support for medication abortion (MA)
Study: 31018852
Drug: Receipt of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receipt of smoking cessation medications while hospitalized
Study: 31018852
Drug: Discharge with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discharge with a prescription
Study: 31018852
Drug: Receipt of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receipt of medication as an inpatient
Study: 24465387
Drug: Brief psychodynamic
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief psychodynamic interpersonal therapy (PIT)
Study: 22436453
Drug: Selenium yeast
Normalized name: Selenium Yeast
DrugBank: Selenium (DB11135)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium yeast (200 μg/day) supplementation for 3 years
Study: 15726878
Drug: Furosemide (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (40 mg) + Triamterene (150 mg)
Study: 15726878
Drug: Triamterene (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triamterene (150 mg)
Study: 12049800
Drug: Topiramate (TPM)
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate (TPM) low dosage (100 mg daily)
Study: 12049800
Drug: Topiramate (TPM)
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate (TPM) medium dosage (200 mg daily)
Study: 10090547
Drug: High-dose inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose inhaled budesonide (1600 microg d(-1) for 3 d and 800 microg for 7 d)
Study: 10090547
Drug: Oral betamethasone
Normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral betamethasone (6, 4 and 2 mg for 3 d)
Study: 7788149
Drug: Prednisone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (10 mg/day for first 12 weeks, tapering to 7.5 mg/day for weeks 13-14, 5 mg/day for weeks 15-16, and 2.5 mg/day for weeks 17-18)
Study: 7788149
Drug: Prednisone (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (after tapering)
Study: 25968407
Drug: Pravastatin 80
Normalized name: pravastatin 80 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 80 mg
Study: 19138366
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of testosterone and vardenafil
Study: 15009968
Drug: Inspiring nitric
Normalized name: Nitric Acid
DrugBank: Nitric acid (DB15995)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiring nitric oxide (NO) at 20±1 mg/L for 30 minutes before admission and urokinase (150x10^4 U) intravenously injected with 0.9% sodium chloride within 30 minutes
Study: 15009968
Drug: Urokinase treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urokinase treatment as in test group
Study: 9845708
Drug: Oral itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral itraconazole (200 mg daily)
Study: 1675705
Drug: Levamisole, 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole, 2.5 mg/kg on alternate days (31 patients)
Study: 18422579
Drug: Choreito (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choreito (7.5 g/day)
Study: 12696391
Drug: Intervention 2:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention 2: Brief (5‐8 minutes) structured medical counselling for tobacco quitting, followed by reinforcement advice on 3 occasions during 3 months, accompanied by nicotine patches individualized according to nicotine dependence.
Study: 9068017
Drug: 39 mmol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 39 mmol/L bicarbonate-buffered CAPD solution
Study: 9068017
Drug: 34 mmol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 34 mmol/L bicarbonate-buffered CAPD solution
Study: 8446394
Drug: Cefetamet pivoxil
Normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefetamet pivoxil 10 mg/kg b.i.d. for 7 days (n = 134)
Study: 8446394
Drug: Cefaclor 13.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor 13.5 mg/kg t.i.d. for 7 days (n = 136)
Study: 3510320
Drug: Cefotaxime (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime (2 intravenous doses preoperatively)
Study: 30819765
Drug: Bevacizumab +
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab + radiation therapy + temozolomide
Study: 24993838
Drug: Gentamicin collagen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin collagen implant (GCI)
Study: 22421244
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (amphotericin B 1 mg/kg per day and 5FC 100 mg/kg per day for 2 weeks)
Study: 22421244
Drug: IFNγ two
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFNγ two doses (standard therapy plus IFNγ1b 100 μg on days 1 and 3)
Study: 22421244
Drug: IFNγ six
Normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFNγ six doses (standard therapy plus IFNγ1b 100 μg on days 1, 3, 5, 8, 10, and 12)
Study: 21054874
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil citrate (exact dosage and duration not specified)
Study: 17991308
Drug: Sublingual ET
Normalized name: Sublingual Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual ET (2 mg tablet)
Study: 17991308
Drug: Metered-dose inhaler
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered-dose inhaler delivering 2052 microg of ET
Study: 11865557
Drug: Antipyretic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipyretic treatment during febrile episodes
Study: 11865557
Drug: Oral diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diazepam as intermittent prophylaxis
Study: 11865557
Drug: Continuous anticonvulsant
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous anticonvulsant treatment
Study: 3111166
Drug: 10% glucose
Normalized name: Dextrose 10% Oral Solution [SIMILAC 10% GLUCOSE WATER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% glucose intravenous infusion
Study: 28903957
Drug: Skewed protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skewed protein distribution (10 g at breakfast, 20 g at lunch, and 60 g at dinner; n = 20)
Study: 28903957
Drug: Even protein
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Even protein distribution (30 g each at breakfast, lunch, and dinner; n = 21)
Study: 21491994
Drug: Oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clonidine (5 μg/kg)
Study: 21491994
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 tablet)
Study: 8102399
Drug: Olsalazine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olsalazine (30 mg/kg/day, max 2 g/day)
Study: 8102399
Drug: Sulfasalazine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfasalazine (60 mg/kg/day, max 4 g/day)
Study: 2967028
Drug: acebutolol 200
Normalized name: acebutolol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: acebutolol 200 mg
Study: 29719884
Drug: Software-directed medication
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Software-directed medication history
Study: 29719884
Drug: Paper-based medication
Normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paper-based medication history
Study: 28594615
Drug: Tooth-brushing with
Normalized name: Sus scrofa tooth preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tooth-brushing with concurrent suctioning technique
Study: 21508856
Drug: LY2140023 monohydrate
Normalized name: Lactose Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2140023 monohydrate 5 mg twice daily
Study: 21508856
Drug: LY2140023 monohydrate
Normalized name: Lactose Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2140023 monohydrate 20 mg twice daily
Study: 21508856
Drug: LY2140023 monohydrate
Normalized name: Lactose Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2140023 monohydrate 40 mg twice daily
Study: 21508856
Drug: LY2140023 monohydrate
Normalized name: Lactose Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2140023 monohydrate 80 mg twice daily
Study: 21508856
Drug: Placebo (am)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (am) and 15 mg of olanzapine (pm) daily
Study: 9012279
Drug: Histamine H2-receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine H2-receptor antagonists in conventional dosages
Study: 9012279
Drug: Prokinetic agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prokinetic agents
Study: 3301166
Drug: Indomethacin treatment
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin treatment before feeding
Study: 3301166
Drug: Indomethacin (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (oral dose 2h before measurement)
Study: 20598453
Drug: Combined endocrine
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined endocrine therapy and external‐beam radiotherapy
Study: 16630091
Drug: Magnesium l-lactate
Normalized name: magnesium L-lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium l-lactate (504 mg elemental magnesium daily)
Study: 14681282
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (12.5 mg zinc sulphate daily for 6 days a week for 6 months)
Study: 1636921
Drug: Tramadol and
Normalized name: tramadol and celecoxib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol and metamizole infusion (400 mg tramadol plus 5 g metamizole in 500 ml electrolyte solution)
Study: 1636921
Drug: Tramadol infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol infusion (400 mg tramadol plus 10 ml placebo in 500 ml electrolyte solution) with ibuprofen suppositories (585.2 mg) preoperatively
Study: 1636921
Drug: Tramadol and
Normalized name: tramadol and celecoxib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol and metamizole infusion
Study: 1636921
Drug: Tramadol infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol infusion with ibuprofen suppositories
Study: 31187102
Drug: 30 mg/mL
Normalized name: urea 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/mL ketorolac tromethamine
Study: 27144937
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil citrate 20 mg thrice daily for 4 weeks
Study: 2920584
Drug: Methylprednisolone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (100 mg)
Study: 27189038
Drug: Treatment arms
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment arms comparison
Study: 25881614
Drug: DRV/r once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: DRV/r once-daily (800/100 mg)
Study: 25881614
Drug: DRV/r twice-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: DRV/r twice-daily (600/100 mg)
Study: 23809446
Drug: 12.0‐μg/h fentanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.0‐μg/h fentanyl patch for 72 hours
Study: 23809446
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch and an infusion of 2.5‐mg/mL bupivacaine in a subacromial manner for 72 hours
Study: 8561982
Drug: HIV vaccine
Normalized name: AAV-2 HIV Vaccine
DrugBank: TGAAC09 (DB06363)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV vaccine trial participation
Study: 350264
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of atenolol and adrenaline
Study: 30921609
Drug: Transcranial alternating
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial alternating current stimulation (tACS) at 4 Hz or 30 Hz based on EEG analysis, 5 days/week for 2 weeks followed by physical therapy.
Study: 26152940
Drug: Ophthalmic solution
Normalized name: Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic solution containing an allergen (CPT)
Study: 23550857
Drug: 200 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg sublingual misoprostol
Study: 19249425
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus coumarin (adjunctive anticoagulation)
Study: 15492433
Drug: Benzoyl peroxide-erythromycin
Normalized name: Benzoyl Peroxide-Erythromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzoyl peroxide-erythromycin gel
Study: 3207549
Drug: Bilateral ilioinguinal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral ilioinguinal nerve blockade using 0.5% plain bupivacaine 10 ml to each side
Study: 29427701
Drug: Atorvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (10 mg/day; n=20)
Study: 29427701
Drug: Simvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (10 mg/day; n=20)
Study: 18156881
Drug: Lower tidal
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower tidal volumes of 6 ml/kg and 10 cm H2O PEEP
Study: 18156881
Drug: Higher tidal
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher tidal volumes of 12 ml/kg ideal body weight and no positive end-expiratory pressure (PEEP)
Study: 15696037
Drug: Contrast-enhanced ultrasound
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast-enhanced ultrasound scanning (CUS) with a bolus of 1.5 to 2.4 mL of a second generation blood pool contrast agent
Study: 11796347
Drug: Ruprintrivir (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruprintrivir (4 mg single dose)
Study: 11796347
Drug: Ruprintrivir (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruprintrivir (8 mg single dose)
Study: 11796347
Drug: Ruprintrivir (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruprintrivir (multiple doses every 3 h, six times per day for 7 days)
Study: 10363622
Drug: Caudal tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal tramadol (1 mg/kg)
Study: 10363622
Drug: 0.25% plain
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% plain bupivacaine (0.5 ml/kg)
Study: 3422243
Drug: 0.2% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% chlorhexidine solution
Study: 31927518
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and written education using aspirin booklet
Study: 26727825
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of bevacizumab 1.25 mg/0.05 mL (Avastin)